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Objective: Sensitive biomarkers are needed to understand synovial response to therapy in osteoarthritis
(OA). Dynamic, contrast-enhanced magnetic resonance imaging (DCE MRI) provides quantitative, novel
measures of synovial inﬂammation. This exploratory study examined DCE-assessed synovial response to
intra-articular corticosteroid (IACS).
Methods: People with ACR clinical criteria OA knee underwent 3 T MRI pre- and 2 weeks post-IACS. Five
MRI variables were assessed blindly: total synovial volume (semi-automated computer program), early
enhancement rate (EER) and late enhancement ratio of the entire knee, synovial volume  late
enhancement and a semi-quantitative (SQ) score (six sites scored 0e3). Clinical symptoms were assessed
using pain visual analogue score (VAS) and WOMAC.
Results: 13 participants (5 male, mean age 63, mean pain VAS 66 mm mean body mass index (BMI)
31.3 kg/m2) were included. The majority of MRIs demonstrated no change in SQ score although the DCE
variables changed to some extent in all. There was generally a reduction in synovial volume ((Wilcoxon
test) median (interquartile range (IQR)) reduction 14 cm3 (1, 29)), EER (0.2% (0.3, 0.6)) and late
enhancement ratio (8% (0.5, 41)). Synovial volume  late enhancement ratio demonstrated a sub-
stantive reduction (2250 (930, 5630)) as well as the largest effect size, r ¼ 0.45. There was a median 26%
reduction in EER in participants with good symptomatic response to IACS, contrasting with a 23% in-
crease in those who responded poorly.
Conclusions: DCE MRI may be more sensitive than a SQ score at detecting post-therapy synovial changes.
The association between EER and symptomatic response to IACS may reﬂect a closer relation of this
biomarker to synovial inﬂammation than with volumetric assessment.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Synovitis is common in osteoarthritis (OA) and large cohort
studies using magnetic resonance imaging (MRI) have demon-
strated the association between synovitis and pain in OA1,2. Anti-
inﬂammatory therapies such as intra-articular corticosteroids
(IACS) are an effective treatment for OA pain. Few studies, mostly
using ultrasound (US)3e5, have objectively assessed the synovial.Y.J. Wenham, Leeds Institute
ond Floor, Chapel Allerton
enham).
ternational. Published by Elsevier Lresponse to anti-synovial therapies and changes seen in synovial
inﬂammatory parameters are generally small, and often not asso-
ciated with clinical symptoms at the patient level.
MRI can perform synovial volumetric analysis, either by manual
segmentation or semi-automatedmethods using speciﬁc computer
software that may be time-consuming but are currently the gold
standard for synovial volumemeasurement. Semi-quantitative (SQ)
synovitis scores are more commonly used which are quicker to
perform and have been validated against volumetric analysis6.
Longitudinal, non-contrast MRI studies have demonstrated an
association between an increase in both synovitis and pain2; yet a
similar reduction in synovitis did not associate with reduced pain2.
Whilst the lack of structure-pain relationship may reﬂect thetd. All rights reserved.
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repeat imaging, it may also reﬂect a relative lack of sensitivity of
current MRI scoring systems assessing only synovitis volume.
Dynamic, contrast-enhanced MRI (DCE MRI) measures the rate
of enhancement of synovium by intravenous contrast within the
synovium and offers an alternative measurement of synovial
inﬂammation. Previous small DCE MRI studies, predominantly of
inﬂammatory arthritis, have demonstrated a reduction in both sy-
novial volume and synovial enhancement rate after IACS7,8 and DCE
MRI has also been used in rheumatoid arthritis9 and psoriatic
arthritis.10
This study explored whether a range of DCE MRI parameters
assessing all enhancing synovium within an OA knee could
demonstrate a change in synovitis after IACS treatment over and
above the currently used MRmeasures of synovitis, thus improving
understanding of the association between synovitis and clinical
symptoms as well as providing a novel outcome for clinical trials.Methods
Ethical committee approval was obtained and participants gave
written, informed consent. People fulﬁlling American College of
Rheumatology clinical criteria for knee OA, referred from rheu-
matology secondary care out-patient clinics for IACS due to mod-
erate to severe knee pain, underwent 3 T MRI imaging prior to, and
approximately 2 weeks after IACS. Exclusion criteria included in-
ﬂammatory arthritis, IACS within 8 weeks and recent knee trauma.
After the baseline scan, the knee was injected with 80 mg meth-
ylprednisolone. Participants at baseline and follow-up completed
the Western Ontario and McMasters Universities Osteoarthritis
Index (WOMAC), and 48 h visual analogue score (VAS) scores for
knee pain, patient and physician disease activity. Symptomatic
response to IACS was deﬁned by at least a 20% reduction in
48 h pain VAS at the follow-up visit.
Knee radiographs were scored (KellgreneLawrence (K/L)
method) by a musculoskeletal radiologist (AJG) (intra-reader reli-
ability kappa 0.9).
Images were acquired using a 3T Magnetom Verio scanner
(Siemens, Erlangen, Germany) using a standard eight channel knee
coil or a larger 15 channel coil. 30 3D gradient echo images were
acquired before, during and after administration of ~0.1 mmol/kg
(max dose 10 mmol) Dotarem (Guerbet, France) at 4 ml/s
(TR ¼ 4.3 ms, TE ¼ 2.5 ms, ﬂip-angle ¼ 30, matrix size 256  90,
ﬁeld of view 300  131/330  144 mm, slice thickness 1.3 mm,
GRAPPA with IPAT ¼ 3, acquisition time 10 s). High resolution VIBE
images (TR ¼ 8 ms, TE ¼ 2.9 ms, ﬂip-angle ¼ 30) were acquired
after contrast administration. Synovitis was scored by a musculo-
skeletal radiologist (AJG) blinded to patient data and time order,
using an SQ score (maximum 14) assessing six areas: medial and
lateral parapatellar recesses, suprapatellar pouch, infrapatellar fat
pad (0e3), and the medial and lateral condyles (0e1).6
Total synovial volume was calculated using the Analyze soft-
ware (version 10.0). Difference images were created from the ﬁrst
pre-gadolinium series and the ﬁnal post-gadolinium series.
Semi-automatic segmentation of the enhancing synovium was
performed from the difference images of the entire knee joint using
a combination of thresholding functions and manual correction.
The 3D segmentation was overlaid on the 4D dynamic series and
values for total synovial volume and mean synovial signal intensity
(SI) for each dynamic series generated. The mean early enhance-
ment rate (EER) at 60 s was calculated by the formula:
{[SIt60  SIt0]/[SIt0  60]} 100%, and the late enhancement ratio
by: {[SIt250  SIt0]/SIt0} 100%, where SI represents the mean sy-
novial enhancement at a time point (t).The “total synovial enhancement”, was calculated by multi-
plying the total synovial volume by the late enhancement ratio.
Statistical analysis
This was an exploratory study and was not powered to show
statistical signiﬁcance. Statistical analysis was performed using IBM
SPSS v.20 (IBM, USA). Wilcoxon signed rank test compared the
difference in variables before and after IACS, and Spearman's rank
order correlation test assessed correlation between variables. Effect
sizes for the Wilcoxon signed rank (r) were calculated as the z-
statistic divided by the square root of the total number of
observations11.
The standardised response mean (SRM) assessed sensitivity to
change for each MR variable in this homogenous group of partici-
pants. The modiﬁed Jackknife technique tested whether the dif-
ferences in SRM values between the synovial volumetric analysis
(seen as the gold standard) and the early, late and total synovial
enhancement were signiﬁcant12. A linear regressionmodel predicts
the difference between the SRM of the gold standard variable and
that of a comparative variable. The model intercept coefﬁcient
represents the difference between the SRM of the gold standard
and that of the comparative variable e a negative value the inter-
cept coefﬁcient indicates that the SRM for that variable is lower that
the SRM of the gold standard.
Results
20 participants were recruited (mean age 63 years, mean
48 h pain VAS 73 mm). Data from seven participants were later
excluded due to difﬁculty establishing intravenous access (n ¼ 3),
hardware failure (n ¼ 3); subject movement (n ¼ 1). Participant
demographics are reported in Table I.
All 13 participants had synovitis at baseline, as deﬁned by a
baseline SQ score of >1 (median score 8), (intra-reader reliability
kappa 0.85). As previously reported, the SQ score demonstrated a
marked correlation with total synovial volumetric analysis (rho
0.66, 95% C.I. 0.10e0.87). Five demonstrated a change in SQ score
after IACS, but in the majority the score remained unchanged
(median 0; effect size r ¼ 0.36). In contrast, DCE MRI demonstrated
a change at the individual participant level in synovial volume and
in early, late and total synovial enhancement in all participants,
even in the absence of a change in SQ score (Fig. 1). At the group
level the effect sizes after IACS were generally small for all DCE
variables, but the novel variable, total synovial enhancement
demonstrated a larger effect size (r ¼ 0.45), than for changes in
early (r ¼ 0.18) and late enhancement (r ¼ 0.32) and total synovial
volume (r ¼ 0.33) and SQ synovitis score (r ¼ 0.36) (Table I).
A moderate association was suggested between the late
enhancement ratio and both WOMAC pain score (rho 0.49, 95%
CI 0.11 to 0.9) and 48 h pain VAS (rho 0.41, 0.21 to 0.83), but the
conﬁdence intervals were broad and non-statistically signiﬁcant
from zero. There were no associations between change in clinical
variables and change in MR variables (all rho <0.2 or P > 0.05).
Participants who achieved a good symptomatic response to
IACS had a median 26% reduction (interquartile range (IQR) 6%,
45%) in EER contrasting with a 19% (IQR 32%, 79%) increase in EER
in those who had poor response (effect size r ¼ 0.34, P ¼ 0.086).
There were similar differences in the changes in late static
enhancement (good response, median reduction (IQR) 29% (7%,
39%) vs poor response, median reduction (IQR) 1% (42%, 37%);
r ¼ 0.25; P ¼ 0.199).
The novel variable of total synovial enhancement had the
highest SRM value (0.73) compared with the gold standard of sy-
novial volumetric analysis (0.45). The EER and late enhancement
Table I
Participant demographics and change in MRI variables
Participant demographics (n ¼ 13) Baseline Follow-up P value (Wilcoxon)
Age (years): mean (range) 62 (48e76)
BMI (kg/m2): mean (SD) 31.3 (4)
NSAID usage (patients): n 9
Disease duration (months): median (IQR) 24 (9e60)
K/L score 1 (patients): n 4
K/L score 2 (patients): n 5
K/L score 3 (patients): n 2
K/L score 4 (patients): n 1
K/L score unknown (patients): n 1
Time between MR scans (days): median (IQR) 20 (14e22)
Pain VAS (48 h, mm)
median (IQR) 72 (39e83) 62 (45e69) 0.173
mean (SD) 63 (29) 52 (24)
Patient activity VAS (mm)
median (IQR) 74 (53e86) 49 (35e69) 0.023
mean (SD) 67 (26) 48 (25)
Physician activity VAS (mm)
median (IQR) 56 (47e65) 40 (35e46) 0.006
mean (SD) 57 (12) 40 (14)
WOMAC pain
median (IQR) 10 (8e14) 10 (4e12)* 0.018
mean (SD) 11 (3) 8 (4)
WOMAC stiffness
median (IQR) 5 (3e7) 3 (2e6) 0.035
mean (SD) 5 (2) 3 (2)
WOMAC function
median (IQR) 35 (27e48) 33 (16e39) 0.023
mean (SD) 37 (13) 29 (15)
MR variable: median (IQR) Pre-IACS Post-IACS Reduction Effect size, P value (Wilcoxon)
SQ synovitis score 8 (7e9) 7 (5e9) 0 (0e2) 0.361, 0.066
Total synovial volumetric analysis (cm3) 68 (58e76) 40 (26e68) 14 (1 to 29) 0.336, 0.087
EER (%) 1.33 (1.03e1.54) 0.93 (0.76e1.84) 0.2 (0.3 to 0.6) 0.185, 0.345
Late static enhancement 126 (107e150) 98 (86e157) 8 (0.5 to 41.5) 0.322, 0.100
Total synovial enhancement  101 814 (630e1090) 350 (234e1036) 225 (93 to 563) 0.445, 0.023
SD, standard deviation; WOMAC, Western Ontario and McMaster Universities osteoarthritis index; NSAID, non-steroidal anti-inﬂammatory drug.
* One patient had an increase in WOMAC pain score of 5 points post-steroid. If this patient is excluded from the WOMAC pain analysis, the median pain score reduces from
11.5 to 8.5.
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stant of the intercept coefﬁcient was negative for the SRM of both
the EER (0.337, P ¼ 0.266) and the late static enhancement
(0.239, P ¼ 0.416). However, the novel variable of total synovial
enhancement had a positive constant of the intercept coefﬁcient
(0.274), and the lowest P value (0.072), suggesting that this variable
may be more sensitive to change than standard volumetric analysis
of synovitis.Fig. 1. a) Time-signal enhancement curves demonstrating synovial enhancement (y axis) aft
contrast), before (dark grey line) and after (light grey line) IACS. The EER was calculated at 6
(y axis) after intravenous gadolinium contrast, before (dark grey line) and after (light grey
demonstrating the reduction in total synovial volume (cm3) after IACS.Discussion
This is the ﬁrst study to assess synovial change after an anti-
synovial therapy in a cohort containing only OA subjects, using
DCE MRI measures of both synovial volume and enhancement
applied to the entire enhancing synovium. Previous DCE MRI
studies8,9,13 assessed preselected MR slices or regions of interest
only.er intravenous gadolinium contrast (x axis represents time in seconds post gadoliunium
0 s (x axis). b): Time-signal enhancement curves demonstrating synovial enhancement
line) IACS. The late enhancement ratio was calculated at 250 s (x axis). c): Box plot
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static enhancement were lower than that of the SQ score and the
current gold standard of total synovial volume. The lack of statis-
tical signiﬁcance for the change in the synovial volume likely re-
ﬂects the small numbers; the estimated effect size was moderate
(>0.3). However, combining synovial enhancement rate and vol-
ume in the novel variable of the total synovial enhancement
demonstrated both a greater effect size and SRM than the total
synovial volume. We also noted that DCE MRI detected changes in
the synovial enhancement rates in patients inwhom the SQ scoring
system remained unchanged. However, the number of study par-
ticipants is few and the effect sizes are small, so the results must be
interpreted with caution.
Few imaging studies have assessed change in the synovium after
anti-synovial therapy. US imaging in painful hand OA could not
demonstrate a signiﬁcant difference in synovial thickening or po-
wer Doppler signal after treatment with IM corticosteroid5, despite
an improvement in clinical symptoms. Neither US nor MRI of the
knee have detected a change in synovial thickness/hypertrophy or a
SQ score after treatment of knee OA5,14. Assessing synovial volume
alone, therefore, has not been able to explain the relationship be-
tween synovitis and symptoms.
Synovial histology from a study of 15 people13 demonstrated
that areas of the synoviumwith a rapid contrast enhancement rate
(measured at a similar time-point to our measure of late
enhancement) correlated markedly (r ¼ 0.63) with measures of
histological vascular congestion, but not with other markers of
inﬂammation such as cellular inﬁltrate, lining layer thickness or
oedema13. However, the EER has demonstrated a strong correlationFig. 2. (Figures aed) apply to the same study participant). a) Sagittal 3D, T1-weighted VIBE w
VIBE water excitation image, demonstrating synovial enhancement (arrowed) post-intra
demonstrating areas of synovial enhancement after intravenous gadolinium contrast. Sem
ference images of the entire knee joint and the 3D segmentation was overlaid on the 4D dy
synovial SI curves pre- and post-IACS.with histological synovitis in previous work15. The EER may reﬂect
synovial inﬂammation more accurately than measurements of sy-
novial volume alone, which measure a mixed pathology of in-
ﬂammatory and ﬁbrotic synovium. Our data demonstrated no
correlation between synovial volume and EER, also suggesting that
a greater synovial volume does not necessarily equate to greater
synovial inﬂammation.
The product of volume and enhancement ratio has the advan-
tage of combining measures of extent and degree of synovial
inﬂammation. It may also bemore robust to edge effects as adjacent
synovial ﬂuid is expected to show little enhancement over this time
period, reducing any effects due to change in synovial ﬂuid volume.
This variable demonstrated the highest effect size for change after
IACS and the highest SRM value.
Participants with a good clinical improvement after IACS had a
large median reduction in EER, suggesting it is the reduction in
synovial inﬂammation, as assessed by contrast enhancement rate,
that may be relevant to OA pain, rather than the total volume of
synovial tissue. In inﬂammatory arthritis, the EER reduced after
treatment with IACS and increased in correlation with a return of
symptoms7,15. This is further supported by data from our group,
which showed a reduction in US power Doppler signal after IACS in
painful knee OA, but no signiﬁcant reduction in effusion/synovial
hypertrophy. The OA control group had no change in Doppler
measurements.
This study has limitations, primarily the number of subjects. The
corticosteroid injection was not imaging-guided but did require
prior aspiration of joint ﬂuid. It is unknown whether OA synovitis
and consequently DCE MRI variables may vary in a short timeater excitation image pre-intravenous gadolinium contrast. b) Sagittal 3D, T1-weighted
venous gadolinium contrast. c) Difference image (post-contrast minus pre-contrast)
i-automatic segmentation of the enhancing synovium was performed from such dif-
namic series to calculate values for mean synovial SI for each dynamic series. d) Mean
C.Y.J. Wenham et al. / Osteoarthritis and Cartilage 22 (2014) 1614e16181618period or whether aspiration of joint ﬂuid alone affects the mea-
surement process; future work should include a control group
receiving no anti-synovial therapy.
This pilot study suggests that DCE MRI may offer a novel way of
assessing whole joint synovial inﬂammation, which may be more
sensitive to change than existing SQ methods. This may offer
valuable insights into the synovitis-symptom relationship and aid
in understanding, and perhaps predicting, response to anti-
synovial therapies (Fig. 2).
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